Early detection, risk stratification, and drug target identification in pulmonary arterial hypertension with plasma proteomics
Early detection, risk stratification, and drug target identification in pulmonary arterial hypertension with plasma proteomics
Pulmonary arterial hypertension is a rare condition that is clinically heterogenous and often diagnosed late in disease progression. Plasma proteomics offers the potential to diagnose earlier, risk-stratify patients, and identify new drug targets.
Learning Objectives
- Pulmonary arterial hypertension as a clinical condition
- Applying proteomics to risk stratification
- Combining proteomics with genome-wide association studies to identify protein quantitative trait loci associated with the condition
Christopher Rhodes, MA, Cantab, PhD
Senior British Heart Foundation Science Fellow
Senior Lecturer
Imperial College London
Martin R. Wilkins
Professor of Clinical Pharmacology
Vice Dean of Research
Faculty of Medicine
Imperial College London
Early detection, risk stratification, and drug target identification in pulmonary arterial hypertension with plasma proteomics
A presentation by Christopher Rhodes, MA, Cantab, PhD, and Martin R. Wilkins
More webinars
WebinarFinding the signal: Identifying reproducible biomarkers in high-plex proteomics
In biomarker discovery, the challenge is rarely a lack of data. Rather, it is knowing how to separate meaningful biological signal from technical distraction. This webinar focuses on how to use univariate analysis as a practical and powerful entry point for biomarker discovery in high-plex proteomics studies.
WebinarMore than the sum of its parts: How harmonized proteomic data reveals meaning across disparate clinical cohorts
Proteomics data generated across sites, time points, and workflows can be difficult to compare using standard normalization alone. This webinar shows how harmonization aligns datasets into a shared biological framework and reveals signals across studies and cohorts, highlighted through the GNPC’s analysis of 40,000 patient samples.
WebinarPathways to Digital Health: AI and Omics in Rheumatoid Arthritis
Explore how groundbreaking proteomic research is transforming our understanding of rheumatoid arthritis (RA). In this on-demand webinar, Allan Stensballe, PhD, shares new insights into the molecular landscape of RA-affected synovial tissue, revealing how autoantibodies and protein signatures may hold the key to more precise personalized therapies.